Business Context and Reporting Period
This Form 8-K Current Report was filed by Caribou Biosciences, Inc. on June 1, 2022. The filing serves as a Regulation FD disclosure to announce an upcoming webcast conference call regarding clinical trial data.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a current report focused on a specific corporate event rather than a periodic financial statement.
Material Changes
No material financial changes versus a prior comparable period are reported in this filing. The primary event is the announcement of a future data release.
Guidance, Outlook, and Management Commentary
- Clinical Data Announcement: The Company will host a webcast conference call on Friday, June 10, 2022, at 8:00 am ET.
- Subject Matter: The call will share additional initial clinical data from the ANTLER phase 1 trial of the Company's product candidate CB-010.
- Indication: The trial focuses on patients with relapsed or refractory B cell non-Hodgkin lymphoma (r/r B-NHL).
- Legal Disclaimer: The information in Item 7.01 and the attached press release (Exhibit 99.1) is not deemed "filed" under the Exchange Act and is not subject to Section 18 liabilities unless specifically stated otherwise.
Investor Verification Checklist
- Verify the date and time of the upcoming webcast (June 10, 2022, 8:00 am ET).
- Review the attached press release (Exhibit 99.1) for specific details on the ANTLER trial data to be presented.
- Confirm access details for the live webcast and accompanying presentation as outlined in Exhibit 99.1.
- Note that this filing does not contain updated financial statements; refer to the most recent 10-Q or 10-K for financial health metrics.